A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung)

A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung)

Background: Most non-small cell lung cancers occur in elderly and frequently comorbid patients. Therefore, it is necessary to evaluate the efficacy of biomodulatory active therapy regimen, concertedly interfering with tumor-associated homeostatic pathways to achieve tumor control paralleled by modes...

Full description

Bibliographic Details
Main Authors: Daniel Heudobler, Christian Schulz, Jürgen R. Fischer, Peter Staib, Thomas Wehler, Thomas Südhoff, Thomas Schichtl, Jochen Wilke, Joachim Hahn, Florian Lüke, Martin Vogelhuber, Sebastian Klobuch, Tobias Pukrop, Wolfgang Herr, Swantje Held, Kristine Beckers, Gauthier Bouche, Albrecht Reichle
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Pharmacology
Subjects:
biomodulation
anakoinosis
NSCLC
checkpoint inhibition
pioglitazone
nivolumab
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.599598/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.599598/full

Similar Items